scholarly journals Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years

2020 ◽  
Vol 11 ◽  
Author(s):  
Yvelise Ferro ◽  
Tiziana Montalcini ◽  
Elisa Mazza ◽  
Daniela Foti ◽  
Elvira Angotti ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Randomized Clinical Trial ◽  
Liver Steatosis ◽  
Wild Cardoon

Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial

2002 ◽  
Vol 20 (2) ◽  
pp. 371-378 ◽  
Author(s):  
Hendrik J. Agteresch ◽  
Trinet Rietveld ◽  
Leon G.M. Kerkhofs ◽  
J. Willem O. van den Berg ◽  
J. H. Paul Wilson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trial ◽  
Body Composition ◽  
Body Weight ◽  
Energy Expenditure ◽  
Randomized Clinical Trial ◽  
Energy Intake ◽  
Advanced Lung Cancer ◽  
Control Group ◽  
Muscle Area

PURPOSE: In a randomized clinical trial in patients with advanced non–small-cell lung cancer (NSCLC), infusion with adenosine 5′-triphosphate (ATP) inhibited loss of body weight and quality of life. In the present article, the effects of ATP on body composition, energy intake, and energy expenditure as secondary outcome measures in the same patients are reported. PATIENTS AND METHODS: Patients with NSCLC, stage IIIB or IV, were randomized to receive either 10 intravenous, 30-hour ATP infusions every 2 to 4 weeks or no ATP. Fat mass (FM), fat-free mass (FFM), and arm muscle area were assessed at 4-week intervals for 28 weeks. Food intake, body cell mass (BCM), and resting energy expenditure (REE) were assessed at 8-week intervals for 16 weeks. Between-group differences were tested for statistical significance by repeated-measures analysis of covariance. RESULTS: Fifty-eight patients were randomized (28 ATP, 30 control). No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P = .004), 0.5 kg of FFM (P = .02), 1.8% of arm muscle area (P = .02), and 0.6% of BCM/kg body weight (P = .054) and decreased 568 KJ/d in energy intake (P = .0001). Appetite also remained stable in the ATP group but decreased significantly in the control group (P = .0004). No significant differences in REE between the ATP and control groups were observed. CONCLUSION: The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues. These effects are partly ascribed to maintenance of energy intake.

Randomized Clinical Trial of Balance-Based Torso Weighting for Improving Upright Mobility in People with Multiple Sclerosis

2009 ◽  
Vol 23 (8) ◽  
pp. 784-791 ◽  
Author(s):  
Gail L. Widener ◽  
Diane D. Allen ◽  
Cynthia Gibson-Horn
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Body Weight ◽  
Randomized Clinical Trial ◽  
Phase 1 ◽  
Gait Velocity ◽  
Control Group ◽  
Phase 2 ◽  
Timed Up And Go ◽  
Standard Weight

Background. Torso weighting has sometimes been effective for improving upright mobility in people with multiple sclerosis, but parameters for weighting have been inconsistent. Objective. To determine whether balance-based torso weighting (BBTW) has immediate effects on upright mobility in people with multiple sclerosis. Methods. This was a 2-phase randomized clinical trial. In phase 1, 36 participants were randomly assigned to experimental and control groups. In phase 2, the control group was subsequently randomized into 2 groups with alternate weight-placement. Tests of upright mobility included: timed up and go (TUG), sharpened Romberg, 360-degree turns, 25-foot walk, and computerized platform posturography. Participants were tested at baseline and again with weights placed according to group membership. In both phases, a physical therapist assessed balance for the BBTW group and then placed weights to decrease balance loss. In phase 1, the control group had no weights placed. In phase 2, the alternate treatment group received standard weight placement of 1.5% body weight. Results. People with BBTW showed a significant improvement in the 25-foot walk ( P = .01) over those with no weight, and the TUG ( P = .01) over those with standard weight placement. BBTW participants received an average of 0.5 kg, less than 1.5% of any participant’s body weight. Conclusion. BBTW can have immediate advantages over a nonweighted condition for gait velocity and over a standardized weighted condition for a functional activity in people with multiple sclerosis (MS) who are ambulatory but have balance and mobility abnormalities.

Hypocaloric diet with lower meal frequency did not affect weight loss, body composition and insulin responsiveness, but improved lipid profile: a randomized clinical trial

2021 ◽  
Author(s):  
Érika Duarte Grangeiro ◽  
Mariana Silva Trigueiro ◽  
Leysimar de Oliveira Siais ◽  
Hilana Moreira Paiva ◽  
Mauro Sola-Penna ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Body Composition ◽  
Body Weight ◽  
Lipid Profile ◽  
Randomized Clinical Trial ◽  
Body Weight Loss ◽  
Hypocaloric Diet ◽  
Meal Frequency ◽  
Insulin Responsiveness

Dietary approaches are essential to control obesity, but the effectiveness of changes in meal frequency (MF) as a strategy for body weight loss or maintenance remain unclear.

The effects of triple therapy (acupuncture, diet and exercise) on body weight: a randomized, clinical trial

2009 ◽  
Vol 33 (5) ◽  
pp. 583-587 ◽  
Author(s):  
M Nourshahi ◽  
S Ahmadizad ◽  
H Nikbakht ◽  
M A Heidarnia ◽  
E Ernst
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Randomized Clinical Trial ◽  
Triple Therapy ◽  
Diet And Exercise

scholarly journals Efficacy of fructooligosaccharide versus placebo for treatment of acute diarrhea in children: A double-blind randomized clinical trial

2016 ◽  
Vol 45 (2) ◽  
pp. 65
Author(s):  
Reni Suryanty ◽  
Supriatmo Supriatmo ◽  
Berlian Hasibuan ◽  
Atan Baas Sinuhaji
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Placebo Group ◽  
Randomized Clinical Trial ◽  
Outpatient Clinic ◽  
Acute Diarrhea ◽  
Pediatric Patients ◽  
Inclusion Criteria ◽  
Double Blind ◽  
Significant Difference

Objective To compare the efficacy of fructooligosaccharide (FOS)versus placebo in pediatric patients with acute diarrhea with re-gard to duration and frequency of diarrhea and the volume andconsistency of the stools.Methods This double-blind randomized clinical trial was carriedout from July to November 2003 in the pediatric intensive careunit, outpatient clinic, and pediatric ward of Adam Malik Hospitaland Pirngadi Hospital, Medan. Subjects were children and infantsaged 4 to 24 months suffering from acute diarrhea without dehy-dration or with mild to moderate dehydration whose parents gaveconsent. Children included in this trial received tablets of either600 mg FOS or 761 mg fructulin as placebo. Patients with mild tomoderate dehydration were initially rehydrated according to theWHO protocol. Afterwards, 10 tablets of FOS or placebo were givento each subject to be taken twice daily. In subjects without dehy-dration, the tablets were given by their parents. Daily follow-upwas performed, in which body weight, temperature, duration andfrequency of diarrhea, and the volume and consistency of stoolswere recorded. For outpatients, home visits were made.Results Out of 142 children who met inclusion criteria, 135 com-pleted the study. These consisted of 68 children in the FOS groupand 67 in the placebo group. Subjects were mostly <12 months ofage (57.0%), male (57.8%), and moderately malnourished (34.1%).There was no statistically significant difference between both groupsin the duration and frequency of diarrhea and the volume and con-sistency of stools (P>0.05).Conclusion There is no effect of the administration of FOS assupplemental therapy on the duration and frequency of diarrheaand on the volume and consistency of stools in children with acutediarrhea

Sign in / Sign up

Export Citation Format

Share Document